Skip to main content
Fig. 2 | BMC Infectious Diseases

Fig. 2

From: A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model

Fig. 2

Re-assessed 4CMenB effectiveness compared with previous estimates. A In red: vaccine effectiveness (VE) of 4CMenB after one to three doses, re-estimated from data reported by Public Health England (PHE) using our Poisson regression model (Eq. 1). B In blue: VE estimated by PHE using the screening method [9]. Bayesian point estimates and 95% credible intervals are marked with red circles and bars. Frequentist point estimates and 95% confidence intervals are marked with blue squares and bars

Back to article page